Common long-term side effects of ADT in treatment of prostate cancer

A new analysis of data from men treated for their prostate cancer between 1992 and 2009 has provided additional information with respect to risks for long-term side effects of androgen deprivation therapy (ADT). … READ MORE …

Risk for DVT and PE as a complication of treatment with ADT

A newly published paper in Prostate Cancer and Prostatic Diseases has confirmed that there is an association between specific forms of androgen deprivation therapy (ADT) and certain types of adverse thromboembolic events. … READ MORE …

Metformin + ADT in treatment of advanced prostate cancer

Yet another study, just published in the Journal of Urology, has indicated a clear association between the use of metformin along with androgen deprivation therapy (ADT) in the treatment of advanced forms of prostate cancer. … READ MORE …

Adjuvant mitoxantrone + prednisone + ADT in treatment of high-risk prostate cancer

About 25 years ago the addition of the combination of mitoxantrone + prednisone to androgen deprivation therapy (ADT) was the first form of chemotherapy ever approved for the treatment of metastatic, castration-resistant prostate cancer. … READ MORE …

Let’s prove the obvious all over again

Once again your sitemaster finds himself flabbergasted at just how often we need to repeat similar experiments to prove the obvious. … READ MORE …

More information about how BAT may work

We know that “cycling” prostate cancer patients on and off high doses on testosterone while they are on androgen deprivation therapy (ADT) appears to have significant therapeutic benefit in at least some patients (see, for example, here). … READ MORE …

Mental health and ADT: an objective review

As regular readers will be aware, there has been some intense debate over the past year or so about whether there is an association between treatment with androgen deprivation therapy (ADT) and risk for dementia. … READ MORE …